enzalutamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
non-steroid antiandrogens 4628 915087-33-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • enzalutamide
  • xtandi
  • MDV3100
  • MDV-3100
Enzalutamide is an androgen receptor inhibitor that acts on different steps in the androgen receptor signaling pathway. Enzalutamide has been shown to competitively inhibit androgen binding to androgen receptors and inhibit androgen receptor nuclear translocation and interaction with DNA. A major metabolite, N‑desmethyl enzalutamide, exhibited similar in vitro activity to enzalutamide. Enzalutamide decreased proliferation and induced cell death of prostate cancer cells in vitro, and decreased tumor volume in a mouse prostate cancer xenograft model.
  • Molecular weight: 464.44
  • Formula: C21H16F4N4O2S
  • CLOGP: 3.35
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 1
  • TPSA: 76.44
  • ALOGS: -5.53
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.16 g O

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.933 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.855 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 46.026 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 3.412 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 7.730 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 27.920 % High 1
herg hERG pIC50 4.962 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.626 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.097 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 5.500 % High 1
kinase-safety-class EIF2AK3,GRK2,PDK1,PDK2,PDK4 5
kinase-selectivity-class GRK2,PDK1 2
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.923 High 1
mh-clint Mouse hepatocyte intrinsic clearance 7.621 High 1
mppb Mouse plasma protein binding (% unbound) 6.740 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 7.211 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 1
pppb Pig plasma protein binding (% unbound) 14.550 % High 1
rh-clint Rat hepatocyte intrinsic clearance 2.642 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 52.760 % High 1
rppb Rat plasma protein binding (% unbound) 5.900 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 38.905 uM High 1

Approvals:

DateAgencyCompanyOrphan
March 24, 2014 PMDA Astellas Pharma Inc
Aug. 31, 2012 FDA ASTELLAS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 51.40 44.77 17 254 106853 90521323

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Malignant neoplasm progression 5883.05 16.48 2704 44980 105696 42467955
Prostatic specific antigen increased 3997.02 16.48 1244 46440 15681 42557970
Death 1771.57 16.48 2380 45304 468805 42104846
Fatigue 1228.73 16.48 1925 45759 433716 42139935
Underdose 1035.28 16.48 460 47224 16206 42557445
Hot flush 938.84 16.48 471 47213 21880 42551771
Product size issue 711.61 16.48 168 47516 637 42573014
Metastases to bone 586.30 16.48 300 47384 14509 42559142
Decreased appetite 434.23 16.48 775 46909 192362 42381289
Dysphagia 433.76 16.48 468 47216 72251 42501400
Product use complaint 406.41 16.48 135 47549 2096 42571555
Product storage error 398.81 16.48 211 47473 10929 42562722
Asthenia 366.13 16.48 901 46783 279892 42293759
Prostate cancer metastatic 296.69 16.48 146 47538 6483 42567168
Prostate cancer 268.88 16.48 289 47395 44354 42529297
Hormone-refractory prostate cancer 266.73 16.48 81 47603 923 42572728
Osteonecrosis of jaw 251.68 16.48 192 47492 18857 42554794
Prescribed underdose 234.14 16.48 145 47539 10137 42563514
Bone pain 232.30 16.48 201 47483 23591 42550060
Prostatic specific antigen abnormal 188.81 16.48 61 47623 863 42572788
Back pain 175.62 16.48 447 47237 141329 42432322
Off label use 150.59 16.48 306 47378 638029 41935622
Toxicity to various agents 142.54 16.48 40 47644 229096 42344555
Product physical issue 138.80 16.48 69 47615 3130 42570521
Dizziness 126.04 16.48 582 47102 248672 42324979
Metastases to lymph nodes 112.80 16.48 75 47609 5923 42567728
Fall 101.56 16.48 524 47160 233996 42339655
Spinal cord compression 97.24 16.48 60 47624 4164 42569487
Cancer pain 95.94 16.48 56 47628 3511 42570140
Acute kidney injury 93.31 16.48 168 47516 367169 42206482
Pyrexia 92.44 16.48 189 47495 393853 42179798
Intentional underdose 89.02 16.48 33 47651 717 42572934
Muscular weakness 83.92 16.48 244 47440 83254 42490397
Completed suicide 79.21 16.48 8 47676 96457 42477194
Febrile neutropenia 78.59 16.48 56 47628 185647 42388004
Nausea 70.97 16.48 716 46968 396083 42177568
Foreign body in respiratory tract 64.52 16.48 18 47666 148 42573503
Hypotension 64.26 16.48 119 47565 257512 42316139
Dysgeusia 61.35 16.48 125 47559 34064 42539587
Prostate cancer recurrent 61.15 16.48 28 47656 1055 42572596
Circumstance or information capable of leading to medication error 60.98 16.48 37 47647 2491 42571160
Pneumonia 60.63 16.48 255 47429 421894 42151757
Blood testosterone increased 59.81 16.48 31 47653 1536 42572115
Malaise 59.13 16.48 423 47261 211733 42361918
Peripheral swelling 58.82 16.48 228 47456 90042 42483609
Product use in unapproved indication 58.74 16.48 72 47612 184384 42389267
Hereditary optic atrophy 58.69 16.48 14 47670 56 42573595
Asthma 57.33 16.48 3 47681 62311 42511340
Treatment noncompliance 56.42 16.48 128 47556 37544 42536107
Memory impairment 53.57 16.48 150 47534 50072 42523579
Foreign body 53.48 16.48 25 47659 988 42572663
BRCA1 gene mutation 52.82 16.48 13 47671 61 42573590
Infusion related reaction 52.74 16.48 4 47680 60802 42512849
Bone lesion 52.62 16.48 38 47646 3428 42570223
Condition aggravated 52.19 16.48 136 47548 260618 42313033
Investigation 49.13 16.48 23 47661 912 42572739
Restless legs syndrome 48.83 16.48 57 47627 9557 42564094
Metastases to liver 47.83 16.48 74 47610 16252 42557399
Oxygen saturation decreased 46.80 16.48 8 47676 64679 42508972
Drug hypersensitivity 46.05 16.48 27 47657 99362 42474289
Rhabdomyolysis 44.19 16.48 16 47668 78003 42495648
Malignant spinal cord compression 44.15 16.48 13 47671 132 42573519
Marasmus 43.82 16.48 21 47663 878 42572773
Hydronephrosis 43.81 16.48 60 47624 11805 42561846
Haematuria 43.51 16.48 153 47531 57646 42516005
BRCA2 gene mutation 43.32 16.48 11 47673 60 42573591
Urinary tract infection 42.93 16.48 222 47462 99062 42474589
COVID-19 41.58 16.48 41 47643 115907 42457744
Insomnia 41.54 16.48 250 47434 118003 42455648
Product availability issue 40.71 16.48 33 47651 3534 42570117
Cerebrovascular accident 40.46 16.48 215 47469 96945 42476706
Wheezing 39.13 16.48 7 47677 54774 42518877
Breast tenderness 39.00 16.48 19 47665 824 42572827
Metastasis 38.49 16.48 36 47648 4669 42568982
Product packaging quantity issue 38.40 16.48 22 47662 1331 42572320
Metastases to spine 38.40 16.48 30 47654 3047 42570604
Arthralgia 38.29 16.48 374 47310 204864 42368787
Blood creatinine increased 38.19 16.48 40 47644 109963 42463688
Cough 37.85 16.48 90 47594 178013 42395638
Therapeutic product effect incomplete 37.78 16.48 16 47668 70923 42502728
Cardiac failure 36.95 16.48 225 47459 106631 42467020
Choking 36.51 16.48 40 47644 6258 42567393
C-reactive protein increased 36.06 16.48 13 47671 63547 42510104
Ageusia 35.97 16.48 54 47630 11551 42562100
Drug ineffective 35.70 16.48 939 46745 629258 41944393
Blood urine present 35.52 16.48 54 47630 11679 42561972
Intercepted product storage error 35.42 16.48 14 47670 364 42573287
Psoriasis 35.18 16.48 6 47678 48598 42525053
Respiratory failure 32.95 16.48 58 47626 128074 42445577
Hypoxia 32.26 16.48 19 47665 69767 42503884
Plasma cell myeloma 32.05 16.48 7 47677 47571 42526080
Constipation 31.36 16.48 298 47386 161993 42411658
Rheumatoid arthritis 31.25 16.48 5 47679 42435 42531216
Coma 30.30 16.48 11 47673 53543 42520108
Mucosal inflammation 29.93 16.48 9 47675 49365 42524286
Sinusitis 29.82 16.48 8 47676 47284 42526367
Anaemia 29.69 16.48 459 47225 279819 42293832
Adverse event 29.65 16.48 75 47609 23565 42550086
Urinary tract obstruction 29.49 16.48 29 47655 4002 42569649
Balance disorder 29.12 16.48 118 47566 47527 42526124
Agitation 29.04 16.48 18 47666 64296 42509355
Septic shock 28.92 16.48 36 47648 91636 42482015
Intentional product use issue 28.63 16.48 23 47661 71810 42501841
Metastases to lung 28.31 16.48 48 47636 11376 42562275
Weight decreased 27.83 16.48 355 47329 207593 42366058
Poor quality product administered 27.72 16.48 22 47662 2286 42571365
Multiple organ dysfunction syndrome 27.69 16.48 41 47643 96994 42476657
Bradycardia 27.57 16.48 33 47651 85451 42488200
White blood cell count decreased 27.46 16.48 51 47633 110345 42463306
Aggression 26.86 16.48 8 47676 44155 42529496
Feeling abnormal 26.73 16.48 151 47533 69635 42504016
Hypoglycaemia 26.68 16.48 17 47667 59837 42513814
Tachycardia 26.67 16.48 45 47639 101042 42472609
Gynaecomastia 26.25 16.48 49 47635 12518 42561133
Lower respiratory tract infection 25.92 16.48 7 47677 41199 42532452
Renal failure 25.72 16.48 79 47605 143647 42430004
Cardio-respiratory arrest 25.67 16.48 17 47667 58619 42515032
Metastases to bladder 25.59 16.48 8 47676 101 42573550
Wrong technique in product usage process 25.58 16.48 105 47579 42530 42531121
Bladder tamponade 25.44 16.48 13 47671 625 42573026
Suicidal ideation 25.42 16.48 11 47673 48150 42525501
Drug ineffective for unapproved indication 25.25 16.48 10 47674 46153 42527498
Stress urinary incontinence 25.17 16.48 8 47676 107 42573544
Stress 25.15 16.48 9 47675 44203 42529448
Cardiac arrest 25.04 16.48 53 47631 109267 42464384
Pelvic pain 24.91 16.48 24 47660 3230 42570421
Abdominal pain 24.86 16.48 119 47565 190352 42383299
Retroperitoneal lymphadenopathy 24.59 16.48 15 47669 1019 42572632
Prostatic specific antigen decreased 24.39 16.48 9 47675 193 42573458
Peri-implantitis 24.15 16.48 8 47676 123 42573528
Foreign body in throat 24.14 16.48 12 47672 544 42573107
Neutropenia 24.09 16.48 128 47556 199303 42374348
Blood creatine phosphokinase increased 24.03 16.48 12 47672 48326 42525325
Blood testosterone abnormal 23.88 16.48 12 47672 557 42573094
Blood urea increased 23.84 16.48 4 47680 32789 42540862
Cognitive disorder 23.62 16.48 88 47596 34084 42539567
Drug reaction with eosinophilia and systemic symptoms 23.20 16.48 9 47675 42066 42531585
Urethral intrinsic sphincter deficiency 23.18 16.48 5 47679 11 42573640
Vision blurred 23.14 16.48 120 47564 53579 42520072
Respiratory distress 22.97 16.48 9 47675 41811 42531840
Disease progression 21.70 16.48 251 47433 143405 42430246
Neuroendocrine carcinoma 21.45 16.48 11 47673 533 42573118
Fracture 21.35 16.48 35 47649 8068 42565583
Infection 21.20 16.48 60 47624 112008 42461643
Follicular cystitis 20.95 16.48 4 47680 3 42573648
Skin lesion 20.46 16.48 3 47681 27171 42546480
Stomatitis 20.19 16.48 16 47668 50313 42523338
Toxic epidermal necrolysis 20.04 16.48 3 47681 26747 42546904
Bone cancer metastatic 19.96 16.48 8 47676 216 42573435
Productive cough 19.94 16.48 17 47667 51550 42522101
Seizure 19.73 16.48 214 47470 120347 42453304
Second primary malignancy 19.58 16.48 37 47647 9538 42564113
Colitis ulcerative 19.46 16.48 3 47681 26172 42547479
Anaphylactic reaction 19.24 16.48 12 47672 42731 42530920
Ascites 19.22 16.48 21 47663 56657 42516994
Metabolic acidosis 18.97 16.48 18 47666 51840 42521811
Injection site pain 18.96 16.48 22 47662 57776 42515875
Bronchitis 18.94 16.48 15 47669 47186 42526465
Lymphocyte count decreased 18.92 16.48 4 47680 27805 42545846
Injection site granuloma 18.75 16.48 5 47679 34 42573617
Deep vein thrombosis 18.73 16.48 36 47648 76921 42496730
Amnesia 18.64 16.48 72 47612 28365 42545286
Product odour abnormal 18.48 16.48 12 47672 910 42572741
Pathological fracture 18.39 16.48 26 47658 5267 42568384
Obstructive airways disorder 18.04 16.48 3 47681 24756 42548895
Performance status decreased 17.62 16.48 24 47660 4696 42568955
Hospice care 17.54 16.48 33 47651 8480 42565171
Neuroendocrine carcinoma of prostate 17.52 16.48 5 47679 45 42573606
Sepsis 17.44 16.48 141 47543 199193 42374458
Product expiration date issue 17.39 16.48 3 47681 0 42573651
Drug level increased 17.35 16.48 4 47680 26196 42547455
Acute respiratory distress syndrome 17.34 16.48 6 47678 30102 42543549
Cerebral infarction 17.33 16.48 75 47609 31094 42542557
Hip fracture 17.16 16.48 43 47641 13429 42560222
Pharyngeal cancer 17.05 16.48 5 47679 50 42573601
Haemoptysis 16.91 16.48 16 47668 46151 42527500
Nocturia 16.86 16.48 40 47644 12072 42561579
Chills 16.61 16.48 52 47632 94014 42479637

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Prostatic specific antigen increased 4105.67 18.55 923 34806 11588 110541982
Malignant neoplasm progression 4033.62 18.55 1656 34073 172911 110380659
Death 1531.77 18.55 1470 34259 697399 109856171
Fatigue 777.38 18.55 1393 34336 1214565 109339005
Hot flush 640.81 18.55 346 35383 65690 110487880
Underdose 569.61 18.55 316 35413 63238 110490332
Product size issue 492.73 18.55 102 35627 829 110552741
Metastases to bone 477.09 18.55 223 35506 31149 110522421
Prostate cancer 426.86 18.55 219 35510 37422 110516148
Decreased appetite 383.23 18.55 607 35122 475239 110078331
Asthenia 337.14 18.55 708 35021 688291 109865279
Prostate cancer metastatic 298.96 18.55 96 35633 4847 110548723
Osteonecrosis of jaw 255.25 18.55 171 35558 47846 110505724
Product use complaint 251.23 18.55 79 35650 3724 110549846
Dysphagia 244.50 18.55 274 35455 153326 110400244
Hormone-refractory prostate cancer 202.01 18.55 49 35680 861 110552709
Bone pain 177.81 18.55 156 35573 64977 110488593
Prostatic specific antigen abnormal 168.48 18.55 40 35689 639 110552931
Back pain 154.38 18.55 358 35371 370638 110182932
Product storage error 139.10 18.55 87 35642 21641 110531929
Prescribed underdose 129.69 18.55 131 35598 65043 110488527
Cancer pain 124.57 18.55 55 35674 6717 110546853
Infusion related reaction 109.20 18.55 3 35726 381159 110172411
Prostate cancer recurrent 93.86 18.55 27 35702 935 110552635
Metastases to lymph nodes 88.27 18.55 57 35672 14975 110538595
Drug hypersensitivity 85.11 18.55 21 35708 454069 110099501
Dizziness 84.29 18.55 446 35283 697747 109855823
Toxicity to various agents 83.03 18.55 26 35703 480529 110073041
Intentional underdose 82.27 18.55 31 35698 2521 110551049
Rheumatoid arthritis 80.17 18.55 4 35725 299609 110253961
Blood testosterone increased 79.76 18.55 26 35703 1376 110552194
Haematuria 79.35 18.55 115 35614 82890 110470680
Bone lesion 76.73 18.55 40 35689 7047 110546523
Fall 74.50 18.55 388 35341 603094 109950476
Hereditary optic atrophy 72.05 18.55 14 35715 79 110553491
Anaemia 71.89 18.55 358 35371 546728 110006842
Product physical issue 70.99 18.55 34 35695 5002 110548568
Sinusitis 70.65 18.55 7 35722 296681 110256889
Spinal cord compression 68.79 18.55 38 35691 7514 110546056
Cardiac failure 68.17 18.55 172 35557 187454 110366116
Asthma 68.07 18.55 3 35726 250288 110303282
Lower respiratory tract infection 65.83 18.55 3 35726 243103 110310467
Wheezing 60.82 18.55 6 35723 255224 110298346
Dysgeusia 59.79 18.55 92 35637 69893 110483677
Malignant spinal cord compression 58.43 18.55 13 35716 153 110553417
Systemic lupus erythematosus 58.01 18.55 7 35722 254331 110299239
Stomatitis 57.95 18.55 9 35720 270233 110283337
Arthropathy 56.43 18.55 12 35717 287510 110266060
Muscular weakness 55.01 18.55 191 35538 248277 110305293
Marasmus 52.56 18.55 20 35709 1671 110551899
Completed suicide 52.13 18.55 8 35721 242373 110311197
Metastases to spine 51.75 18.55 28 35701 5315 110548255
Impaired healing 51.45 18.55 3 35726 196714 110356856
Hepatic enzyme increased 50.86 18.55 20 35709 320872 110232698
Hydronephrosis 49.48 18.55 46 35683 20619 110532951
Cerebrovascular accident 48.81 18.55 149 35580 181135 110372435
Disease progression 48.41 18.55 181 35548 243853 110309717
Therapeutic product effect decreased 48.34 18.55 10 35719 244306 110309264
Metastases to liver 47.65 18.55 58 35671 35328 110518242
Foreign body in respiratory tract 47.04 18.55 13 35716 388 110553182
Blood cholesterol increased 44.93 18.55 4 35725 184781 110368789
Restless legs syndrome 44.46 18.55 47 35682 24579 110528991
Blister 43.58 18.55 10 35719 227366 110326204
Cerebral infarction 42.67 18.55 67 35662 51771 110501799
Type 2 diabetes mellitus 42.65 18.55 4 35725 177228 110376342
Off label use 42.23 18.55 298 35431 1499887 109053683
Product use in unapproved indication 41.59 18.55 50 35679 447327 110106243
Drug interaction 41.41 18.55 290 35439 499893 110053677
Migraine 40.98 18.55 4 35725 171648 110381922
Constipation 40.62 18.55 225 35504 357561 110196009
Blood urine present 39.79 18.55 44 35685 24201 110529369
Oesophageal ulcer haemorrhage 39.76 18.55 14 35715 938 110552632
Gynaecomastia 39.24 18.55 29 35700 9461 110544109
Joint swelling 38.56 18.55 52 35677 442793 110110777
Alopecia 38.07 18.55 37 35692 364716 110188854
Condition aggravated 37.82 18.55 117 35612 734719 109818851
Nasopharyngitis 37.80 18.55 43 35686 394318 110159252
Hypersensitivity 37.71 18.55 45 35684 403953 110149617
C-reactive protein increased 37.22 18.55 12 35717 217907 110335663
Ageusia 36.37 18.55 38 35691 19607 110533963
Interstitial lung disease 36.08 18.55 113 35616 139221 110414349
Weight increased 35.81 18.55 50 35679 419594 110133976
Therapeutic product effect incomplete 35.37 18.55 14 35715 223791 110329779
Blood testosterone abnormal 35.31 18.55 10 35719 327 110553243
Discomfort 34.64 18.55 13 35716 214694 110338876
Liver injury 34.63 18.55 4 35725 150409 110403161
Inflammation 34.16 18.55 10 35719 193228 110360342
Seizure 33.52 18.55 151 35578 221034 110332536
Pyrexia 33.41 18.55 163 35566 898102 109655468
Product availability issue 32.37 18.55 24 35705 7866 110545704
Oxygen saturation decreased 31.94 18.55 6 35723 156976 110396594
Nocturia 31.69 18.55 33 35696 16957 110536613
Metastasis 31.37 18.55 24 35705 8243 110545327
Urinary tract obstruction 31.31 18.55 20 35709 5157 110548413
Bursitis 31.08 18.55 3 35726 129915 110423655
Infection 31.05 18.55 43 35686 362157 110191413
Prostatic specific antigen decreased 30.68 18.55 7 35722 93 110553477
Balance disorder 30.61 18.55 95 35634 116465 110437105
Peri-implantitis 30.04 18.55 8 35721 207 110553363
Second primary malignancy 30.01 18.55 33 35696 18035 110535535
Treatment noncompliance 29.77 18.55 70 35659 72920 110480650
Weight decreased 29.09 18.55 254 35475 467803 110085767
Joint range of motion decreased 28.66 18.55 3 35726 121829 110431741
Intentional product use issue 28.44 18.55 23 35706 247883 110305687
Vision blurred 28.37 18.55 99 35630 128923 110424647
Urticaria 28.19 18.55 37 35692 318820 110234750
Ill-defined disorder 27.93 18.55 8 35721 156845 110396725
Urinary retention 27.53 18.55 66 35663 69617 110483953
Lung disorder 27.26 18.55 12 35717 180035 110373535
Subdural haematoma 27.11 18.55 45 35684 36409 110517161
Metastases to lung 26.61 18.55 35 35694 23028 110530542
Mobility decreased 26.04 18.55 23 35706 237399 110316171
Erectile dysfunction 25.94 18.55 31 35698 18525 110535045
Follicular cystitis 25.91 18.55 4 35725 3 110553567
Hypocalcaemia 24.85 18.55 61 35668 65305 110488265
Retroperitoneal lymphadenopathy 24.29 18.55 11 35718 1425 110552145
Circumstance or information capable of leading to medication error 23.93 18.55 17 35712 5216 110548354
Gastrointestinal disorder 23.59 18.55 26 35703 241926 110311644
Injury 23.58 18.55 14 35715 177251 110376319
Swelling 23.35 18.55 49 35680 350992 110202578
Product use issue 22.91 18.55 41 35688 311654 110241916
Urinary tract infection 22.89 18.55 182 35547 326100 110227470
Myalgia 22.69 18.55 136 35593 222245 110331325
Malaise 22.61 18.55 323 35406 671496 109882074
Choking 22.38 18.55 26 35703 15084 110538486
Inguinal hernia 22.07 18.55 19 35710 7706 110545864
Cough 21.98 18.55 76 35653 461565 110092005
Product packaging quantity issue 21.93 18.55 11 35718 1788 110551782
Urethral intrinsic sphincter deficiency 21.92 18.55 4 35725 15 110553555
Hypersomnia 21.35 18.55 35 35694 28026 110525544
Nausea 21.10 18.55 535 35194 1235155 109318415
Hepatic function abnormal 20.92 18.55 70 35659 89225 110464345
Osteoarthritis 20.87 18.55 17 35712 182606 110370964
Foreign body in throat 20.74 18.55 9 35720 1054 110552516
Breast tenderness 20.58 18.55 12 35717 2628 110550942
Gastrooesophageal reflux disease 20.26 18.55 17 35712 179959 110373611
Treatment failure 19.90 18.55 37 35692 277197 110276373
Injection site granuloma 19.46 18.55 5 35724 112 110553458
Atrial fibrillation 19.46 18.55 134 35595 229508 110324062
Stress 19.46 18.55 5 35724 105343 110448227
Neuroendocrine carcinoma 19.43 18.55 8 35721 822 110552748
Haemorrhage urinary tract 19.40 18.55 12 35717 2924 110550646
Drug intolerance 19.30 18.55 67 35662 406445 110147125
Investigation 19.25 18.55 11 35718 2321 110551249
Coma 19.24 18.55 7 35722 117862 110435708
Foreign body 19.18 18.55 12 35717 2983 110550587
Wrong technique in product usage process 19.17 18.55 67 35662 87281 110466289
Postrenal failure 19.02 18.55 8 35721 868 110552702
Wound infection 18.96 18.55 4 35725 96461 110457109
International normalised ratio abnormal 18.90 18.55 16 35713 6341 110547229
Neuroendocrine carcinoma of prostate 18.76 18.55 4 35725 38 110553532
Bronchitis 18.73 18.55 14 35715 157018 110396552
Contusion 18.72 18.55 29 35700 233332 110320238
Prescribed overdose 18.57 18.55 3 35726 87578 110465992

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L02BB04 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ENDOCRINE THERAPY
HORMONE ANTAGONISTS AND RELATED AGENTS
Anti-androgens
FDA MoA N0000000243 Androgen Receptor Antagonists
FDA EPC N0000175560 Androgen Receptor Inhibitor
FDA MoA N0000185506 Cytochrome P450 3A4 Inducers
FDA MoA N0000185507 Cytochrome P450 2C9 Inducers
FDA MoA N0000185607 Cytochrome P450 2C19 Inducers
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:35497 androgen antagonist
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:231911 renoprotective agent

Related Drugs by ATC class:

L02BB Anti-androgens 5 drugs
apalutamidebicalutamidedarolutamideflutamidenilutamide

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Metastasis from malignant tumor of prostate indication 314994000
Malignant tumor of prostate indication 399068003 DOID:10283




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.88 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
40MG XTANDI ASTELLAS N203415 Aug. 31, 2012 RX CAPSULE ORAL 9126941 May 15, 2026 THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC).
40MG XTANDI ASTELLAS N203415 Aug. 31, 2012 RX CAPSULE ORAL 9126941 May 15, 2026 THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
40MG XTANDI ASTELLAS N203415 Aug. 31, 2012 RX CAPSULE ORAL 9126941 May 15, 2026 TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
40MG XTANDI ASTELLAS N203415 Aug. 31, 2012 RX CAPSULE ORAL 9126941 May 15, 2026 TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC) WITH BIOCHEMICAL RECURRENCE (BCR) AT HIGH RISK FOR METASTASIS
40MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL 9126941 May 15, 2026 THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
40MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL 9126941 May 15, 2026 TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
40MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL 9126941 May 15, 2026 TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC) WITH BIOCHEMICAL RECURRENCE (BCR) AT HIGH RISK FOR METASTASIS
80MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL 9126941 May 15, 2026 THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
80MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL 9126941 May 15, 2026 TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
80MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL 9126941 May 15, 2026 TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC) WITH BIOCHEMICAL RECURRENCE (BCR) AT HIGH RISK FOR METASTASIS
40MG XTANDI ASTELLAS N203415 Aug. 31, 2012 RX CAPSULE ORAL 8183274 Aug. 24, 2026 THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC).
40MG XTANDI ASTELLAS N203415 Aug. 31, 2012 RX CAPSULE ORAL 8183274 Aug. 24, 2026 THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PREVIOUSLY RECEIVED DOCETAXEL
40MG XTANDI ASTELLAS N203415 Aug. 31, 2012 RX CAPSULE ORAL 8183274 Aug. 24, 2026 THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
40MG XTANDI ASTELLAS N203415 Aug. 31, 2012 RX CAPSULE ORAL 8183274 Aug. 24, 2026 TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
40MG XTANDI ASTELLAS N203415 Aug. 31, 2012 RX CAPSULE ORAL 8183274 Aug. 24, 2026 TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC) WITH BIOCHEMICAL RECURRENCE (BCR) AT HIGH RISK FOR METASTASIS
40MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL 8183274 Aug. 24, 2026 THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
40MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL 8183274 Aug. 24, 2026 TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
40MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL 8183274 Aug. 24, 2026 TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC) WITH BIOCHEMICAL RECURRENCE (BCR) AT HIGH RISK FOR METASTASIS
80MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL 8183274 Aug. 24, 2026 THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
80MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL 8183274 Aug. 24, 2026 TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
80MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL 8183274 Aug. 24, 2026 TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC) WITH BIOCHEMICAL RECURRENCE (BCR) AT HIGH RISK FOR METASTASIS
40MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL 12502357 Sept. 11, 2033 TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER BY ADMINISTERING A TABLET COMPRISING A SOLID DISPERSION COMPRISING AMORPHOUS ENZALUTAMIDE AND HPMCAS
40MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL 12502357 Sept. 11, 2033 TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER BY ADMINISTERING A TABLET COMPRISING A SOLID DISPERSION COMPRISING AMORPHOUS ENZALUTAMIDE AND HPMCAS
40MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL 12502357 Sept. 11, 2033 TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER WITH BIOCHEMICAL RECURRENCE AT HIGH RISK FOR METASTASIS BY ADMINISTERING A TABLET COMPRISING A SOLID DISPERSION COMPRISING AMORPHOUS ENZALUTAMIDE AND HPMCAS
80MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL 12447128 Sept. 11, 2033 TREATMENT OF NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER WITH BIOCHEMICAL RECURRENCE AT HIGH RISK FOR METASTASIS BY ADMINISTERING TWO TABLETS EACH COMPRISING A SPRAY-DRIED DISPERSION OF 80 MG AMORPHOUS ENZALUTAMIDE AND 400 MG HPMCAS AS CLAIMED
80MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL 12447128 Sept. 11, 2033 TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER BY ADMINISTERING TWO TABLETS EACH COMPRISING A SPRAY-DRIED DISPERSION OF 80 MG AMORPHOUS ENZALUTAMIDE AND 400 MG HPMCAS AS CLAIMED
80MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL 12447128 Sept. 11, 2033 TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER BY ADMINISTERING TWO TABLETS EACH COMPRISING A SPRAY-DRIED DISPERSION OF 80 MG AMORPHOUS ENZALUTAMIDE AND 400 MG HPMCAS AS CLAIMED
80MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL 12502357 Sept. 11, 2033 TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER BY ADMINISTERING A TABLET COMPRISING A SOLID DISPERSION COMPRISING AMORPHOUS ENZALUTAMIDE AND HPMCAS
80MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL 12502357 Sept. 11, 2033 TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER BY ADMINISTERING A TABLET COMPRISING A SOLID DISPERSION COMPRISING AMORPHOUS ENZALUTAMIDE AND HPMCAS
80MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL 12502357 Sept. 11, 2033 TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER WITH BIOCHEMICAL RECURRENCE AT HIGH RISK FOR METASTASIS BY ADMINISTERING A TABLET COMPRISING A SOLID DISPERSION COMPRISING AMORPHOUS ENZALUTAMIDE AND HPMCAS
40MG XTANDI ASTELLAS N203415 Aug. 31, 2012 RX CAPSULE ORAL 12161628 Feb. 23, 2037 TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER TO WHOM RIFAMPIN IS ADMINISTERED WITH THE CO-ADMINISTRATION OF A DAILY DOSE OF 240 MG ENZALUTAMIDE
40MG XTANDI ASTELLAS N203415 Aug. 31, 2012 RX CAPSULE ORAL 12161628 Feb. 23, 2037 TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER TO WHOM RIFAMPIN IS ADMINISTERED WITH THE CO-ADMINISTRATION OF A DAILY DOSE OF 240 MG ENZALUTAMIDE
40MG XTANDI ASTELLAS N203415 Aug. 31, 2012 RX CAPSULE ORAL 12161628 Feb. 23, 2037 TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER TO WHOM RIFAMPIN IS ADMINISTERED WITH THE CO-ADMINISTRATION OF A DAILY DOSE OF 240 MG ENZALUTAMIDE
40MG XTANDI ASTELLAS N203415 Aug. 31, 2012 RX CAPSULE ORAL 12161628 Feb. 23, 2037 TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER WITH BIOCHEMICAL RECURRENCE AT HIGH RISK FOR METASTASIS TO WHOM RIFAMPIN IS ADMINISTERED WITH THE CO-ADMINISTRATION OF A DAILY DOSE OF 240 MG ENZALUTAMIDE
40MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL 12161628 Feb. 23, 2037 TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER TO WHOM RIFAMPIN IS ADMINISTERED WITH THE CO-ADMINISTRATION OF A DAILY DOSE OF 240 MG ENZALUTAMIDE
40MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL 12161628 Feb. 23, 2037 TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER TO WHOM RIFAMPIN IS ADMINISTERED WITH THE CO-ADMINISTRATION OF A DAILY DOSE OF 240 MG ENZALUTAMIDE
40MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL 12161628 Feb. 23, 2037 TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER TO WHOM RIFAMPIN IS ADMINISTERED WITH THE CO-ADMINISTRATION OF A DAILY DOSE OF 240 MG ENZALUTAMIDE
40MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL 12161628 Feb. 23, 2037 TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER WITH BIOCHEMICAL RECURRENCE AT HIGH RISK FOR METASTASIS TO WHOM RIFAMPIN IS ADMINISTERED WITH THE CO-ADMINISTRATION OF A DAILY DOSE OF 240 MG ENZALUTAMIDE
80MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL 12161628 Feb. 23, 2037 TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER TO WHOM RIFAMPIN IS ADMINISTERED WITH THE CO-ADMINISTRATION OF A DAILY DOSE OF 240 MG ENZALUTAMIDE
80MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL 12161628 Feb. 23, 2037 TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER TO WHOM RIFAMPIN IS ADMINISTERED WITH THE CO-ADMINISTRATION OF A DAILY DOSE OF 240 MG ENZALUTAMIDE
80MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL 12161628 Feb. 23, 2037 TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER TO WHOM RIFAMPIN IS ADMINISTERED WITH THE CO-ADMINISTRATION OF A DAILY DOSE OF 240 MG ENZALUTAMIDE
80MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL 12161628 Feb. 23, 2037 TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER WITH BIOCHEMICAL RECURRENCE AT HIGH RISK FOR METASTASIS TO WHOM RIFAMPIN IS ADMINISTERED WITH THE CO-ADMINISTRATION OF A DAILY DOSE OF 240 MG ENZALUTAMIDE

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
40MG XTANDI ASTELLAS N203415 Aug. 31, 2012 RX CAPSULE ORAL Nov. 17, 2026 TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC) WITH BIOCHEMICAL RECURRENCE AT HIGH RISK FOR METASTASIS
40MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL Nov. 17, 2026 TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC) WITH BIOCHEMICAL RECURRENCE AT HIGH RISK FOR METASTASIS
80MG XTANDI ASTELLAS N213674 Aug. 4, 2020 RX TABLET ORAL Nov. 17, 2026 TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC) WITH BIOCHEMICAL RECURRENCE AT HIGH RISK FOR METASTASIS

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Androgen receptor Nuclear hormone receptor ANTAGONIST EC50 7.31 CHEMBL CHEMBL
Glucocorticoid receptor Nuclear hormone receptor Ki 4.85 CHEMBL
Prostate-specific antigen Surface antigen IC50 6.89 CHEMBL
Androgen receptor Transcription factor IC50 6.53 CHEMBL

External reference:

IDSource
93T0T9GKNU UNII
D10218 KEGG_DRUG
4031716 VUID
N0000185726 NUI
4031716 VANDF
C3496793 UMLSCUI
CHEMBL1082407 ChEMBL_ID
15951529 PUBCHEM_CID
DB08899 DRUGBANK_ID
9621 INN_ID
C540278 MESH_SUPPLEMENTAL_RECORD_UI
6812 IUPHAR_LIGAND_ID
1307298 RXNORM
192757 MMSL
28802 MMSL
d07900 MMSL
014630 NDDF
703125003 SNOMEDCT_US
703684000 SNOMEDCT_US
CHEBI:68534 CHEBI
93T0T9GKNU INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Xtandi HUMAN PRESCRIPTION DRUG LABEL 1 0469-0125 CAPSULE 40 mg ORAL NDA 28 sections
Xtandi HUMAN PRESCRIPTION DRUG LABEL 1 0469-0625 TABLET 40 mg ORAL NDA 28 sections
Xtandi HUMAN PRESCRIPTION DRUG LABEL 1 0469-0725 TABLET 80 mg ORAL NDA 28 sections
Xtandi HUMAN PRESCRIPTION DRUG LABEL 1 0469-1125 CAPSULE 40 mg ORAL NDA 28 sections
Xtandi HUMAN PRESCRIPTION DRUG LABEL 1 0469-1725 TABLET 40 mg ORAL NDA 28 sections